Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

microRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1.

Chen X, Zhao M, Huang J, Li Y, Wang S, Harrington CA, Qian DZ, Sun XX, Dai MS.

J Cell Biochem. 2018 Jun;119(6):4945-4956. doi: 10.1002/jcb.26739. Epub 2018 Mar 9.

PMID:
29384218
2.

Systemic Inhibition of CREB is Well-tolerated in vivo.

Li BX, Gardner R, Xue C, Qian DZ, Xie F, Thomas G, Kazmierczak SC, Habecker BA, Xiao X.

Sci Rep. 2016 Oct 3;6:34513. doi: 10.1038/srep34513.

3.

Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity.

Xie F, Li BX, Kassenbrock A, Xue C, Wang X, Qian DZ, Sears RC, Xiao X.

J Med Chem. 2015 Jun 25;58(12):5075-87. doi: 10.1021/acs.jmedchem.5b00468. Epub 2015 Jun 5.

4.

Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase.

Liu Q, Geng H, Xue C, Beer TM, Qian DZ.

Biochim Biophys Acta. 2015 May;1853(5):881-91. doi: 10.1016/j.bbamcr.2015.01.011. Epub 2015 Jan 28.

5.

Carbohydrate-conjugated fluorescent silica nanoprobes for selective detection of galectin-1 and prostate cancer cells.

Jiang K, Wang X, Geng H, Beer TM, Qian DZ, Ramström O, Yan M.

Sci Lett J. 2015;4. pii: 132.

6.

Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.

Liu Q, Harvey CT, Geng H, Xue C, Chen V, Beer TM, Qian DZ.

Prostate. 2013 Jul;73(10):1028-37. doi: 10.1002/pros.22650. Epub 2013 Feb 6.

7.

HIF1α protein stability is increased by acetylation at lysine 709.

Geng H, Liu Q, Xue C, David LL, Beer TM, Thomas GV, Dai MS, Qian DZ.

J Biol Chem. 2012 Oct 12;287(42):35496-505. doi: 10.1074/jbc.M112.400697. Epub 2012 Aug 20.

8.

Cigarette smoke and cancer.

Kachhap S, Keshamouni VG, Qian DZ, Chatterjee A.

J Oncol. 2011;2011:172678. doi: 10.1155/2011/172678. Epub 2011 Aug 29. No abstract available.

9.

HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia.

Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, Qian DZ.

J Biol Chem. 2011 Nov 4;286(44):38095-102. doi: 10.1074/jbc.M111.257055. Epub 2011 Sep 14.

10.

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV.

Sci Transl Med. 2011 Jun 1;3(85):85ra47. doi: 10.1126/scitranslmed.3002004.

11.

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N.

Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.

12.

ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.

Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ.

Cancer Res. 2010 Apr 15;70(8):3239-48. doi: 10.1158/0008-5472.CAN-09-3186. Epub 2010 Apr 13.

13.

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.

Prostate. 2010 Mar 1;70(4):433-42. doi: 10.1002/pros.21077.

14.

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization.

Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL.

Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5. doi: 10.1073/pnas.0909353106. Epub 2009 Oct 1.

15.

Prostate cancer-associated gene expression alterations determined from needle biopsies.

Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM.

Clin Cancer Res. 2009 May 1;15(9):3135-42. doi: 10.1158/1078-0432.CCR-08-1982. Epub 2009 Apr 14.

16.

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells.

Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8. doi: 10.1073/pnas.0812801106. Epub 2009 Jan 23.

17.

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth.

Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86. doi: 10.1073/pnas.0809763105. Epub 2008 Nov 19.

18.

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.

Clin Cancer Res. 2008 Jun 1;14(11):3589-97. doi: 10.1158/1078-0432.CCR-07-4306.

19.

The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.

Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer TM.

Clin Cancer Res. 2008 Jun 1;14(11):3562-70. doi: 10.1158/1078-0432.CCR-07-4649.

20.

Platelets take up the monoclonal antibody bevacizumab.

Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5341-7. Epub 2007 Sep 12.

21.

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.

Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA.

PLoS One. 2007 Sep 5;2(9):e844.

22.

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.

Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R.

Clin Cancer Res. 2007 Jul 15;13(14):4201-8.

23.

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.

Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R.

Prostate. 2007 Aug 1;67(11):1182-93.

PMID:
17520666
24.

Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.

Verheul HM, Qian DZ, Carducci MA, Pili R.

Cancer Chemother Pharmacol. 2007 Aug;60(3):329-39. Epub 2007 Jan 26.

PMID:
17256134
25.

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R.

Mol Cancer Ther. 2007 Jan;6(1):70-81.

26.

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.

Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T.

Prostate. 2006 Dec 1;66(16):1768-78.

PMID:
16955399
27.

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.

Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R.

Cancer Res. 2006 Sep 1;66(17):8814-21.

28.

Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.

Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ Jr, Liu JO.

J Med Chem. 2006 May 4;49(9):2677-80.

PMID:
16640327
29.

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.

Clin Cancer Res. 2006 Jan 15;12(2):634-42.

30.

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.

Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R.

Clin Cancer Res. 2005 May 1;11(9):3535-42.

31.

In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.

Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R.

Prostate. 2005 Jun 15;64(1):20-8.

PMID:
15651062

Supplemental Content

Support Center